Sustained release GLP-1 receptor modulators

US7534763B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Feng Qian · Baltimore, US
• William R. Ewing · Yardley, US
• Claudio Mapelli · Princeton, US
• Douglas James Riexinger · Flemington, US
• Ving Lee · Hillsborough Township, US
• Richard B. Sulsky · Somerville, US
• Yeheng Zhu · Stockton, US
• Tasir Shamsul Haque · Yardley, US
• Rogelio L. Martinez · Plainsboro, US
• Vijay H. Naringrekar · Princeton, US
• Nina Ni · Kendall Park, US
• Lori S. Burton · Lawrence, US

Key dates

• Filing date: Nov 8, 2006
• Grant date: May 19, 2009
• Expiry date: Jan 30, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/26
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.